100XBio key facts
as of Oct 2026- Operator of a biotechnology company intended to offer efficient T-cell research.
- 100XBio is valued at approximately $8.0M as of Oct 2026 (last reported valuation).
- It has raised $480K; the latest was Seed Round ($50K) in Apr 2025.
- Notable investors include Bioincubator, C2I Accelerator.
- Status: Privately Held (backing).
100XBio's last reported valuation, Apr 2025. Nothing priced has surfaced since.
- ·Watch 100XBio: the Monday email on marks, rounds and moves
100XBio funding rounds
No funding rounds for 100XBio are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Who backs 100XBio
2100XBio valuation
100XBio's last reported valuation was $8 million in Apr 2025. No priced round, secondary trade or fund mark has surfaced since.
100XBio investors
2 investors are on record for 100XBio, including Bioincubator and C2I Accelerator.
About 100XBio
Operator of a biotechnology company intended to offer efficient T-cell research. The company develops innovative approaches to streamline the analysis of T-cell antigen specificity and sequencing, enabling researchers and clinicians to understand the diversity and specificity of the receptors, which is important for various aspects of immunology, immunotherapy, and disease diagnosis and treatment.
- Sector
- Healthcare
- HQ
- Woburn, MA, United States
- Founded
- 2023
- Employees
- 2
- Website
- 100xbio.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.